title: [The systemic evaluation and clinical significance of immunological function for advanced lung cancer patients].
abstract: OBJECTIVE
  The actual evaluation of immunological function is significant for studing the tumor development and devising a treatment in time. The aim of this study is to evaluate the immunological function of advanced lung cancer patients systematically, and to discuss the clinical significance.
  
  
  METHODS
  The nucleated cell amounts of advanced lung cancer patients and the healthy individuals were counted. The immune cell subsets and the levels of IL-4, INF-gamma, perforin and granzyme in CD8+T cells by the flow cytometry were measured. The proliferation activity and the inhibition ratio of immune cells to several tumor cell lines were evaluated by MTT assay.
  
  
  RESULTS
  The absolute amounts and subsets of T, B, NK cells of advanced lung cancer patients were lower than the healthy individuals (P < 0.05); However, the proportion of regulatory T cells of advanced lung cancer patients (4.00 +/- 1.84)% was lower than the healthy individuals (1.27 +/- 0.78)% (P < 0.05). The positive rates of IFN-gamma perforin, granzyme in CD8+T cells decreased while them in IL-4 did not in the advanced lung cancer patients compared to the healthy control group (P < 0.05). The proliferation activity of immune cells, the positive rate of PPD masculine and the inhibition ratio to tumor cells in the advanced lung cancer patients was lower than the healthy subsets obviously (P < 0.05).
  
  
  CONCLUSIONS
  There was a significant immune depression in the advanced lung cancer patients compared to the healthy individuals.
authors.affiliation: Department of Biotherapy, Fourth Affiliated Hospital of China Medical University, Shenyang 110032, China.
authors.forename: Tuya
authors.initials: T
authors.lastname: Wulan
authors.forename: Shiyong
authors.initials: S
authors.lastname: Wang
authors.forename: Weili
authors.initials: W
authors.lastname: Du
authors.forename: Hui
authors.initials: H
authors.lastname: Zhang
authors.forename: Yuan
authors.initials: Y
authors.lastname: Zhang
authors.forename: Xue
authors.initials: X
authors.lastname: Zeng
authors.forename: Sa
authors.initials: S
authors.lastname: Liu
authors.forename: Yanping
authors.initials: Y
authors.lastname: Liu
authors.forename: Lu
authors.initials: L
authors.lastname: Zhang
authors.forename: Zhe
authors.initials: Z
authors.lastname: Zhang
authors.forename: Ying
authors.initials: Y
authors.lastname: He
authors.forename: Jialing
authors.initials: J
authors.lastname: Wang
authors.forename: Xiuyan
authors.initials: X
authors.lastname: Wu
mesh_terms: D000328:Adult; D000368:Aged; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology / Q000378:metabolism; D045744:Cell Line, Tumor; D005260:Female; D005434:Flow Cytometry; D053804:Granzymes / Q000378:metabolism; D006801:Humans; D007371:Interferon-gamma / Q000378:metabolism; D015847:Interleukin-4 / Q000378:metabolism; D008175:Lung Neoplasms / Q000276:immunology* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D054353:Perforin / Q000378:metabolism
chemical_list: D054353:Perforin; D015847:Interleukin-4; D007371:Interferon-gamma; D053804:Granzymes